Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAF^V600E-associated thyroid carcinoma.

ABSTRACT:

Background

BRAF^V600E is the most common genetic mutation in differentiated thyroid cancer (DTC) occurring in 60% of patients and drives malignant tumour cell phenotypes including proliferation, metastasis and immune-escape. BRAF^V600E-mutated papillary thyroid cancer (PTC) also displays greatly reduced expression of thyroid differentiation markers, thus tendency to radioactive iodine (RAI) refractory and poor prognosis. Therefore, understanding the molecular mechanisms and main oncogenic events underlying BRAF^V600E will guide future therapy development.

Methods

Bioinformatics and clinical specimen analyses, genetic manipulation of BRAF^V600E-induced PTC model, functional and mechanism exploration guided with transcriptomic screening,

SUBMITTER: Zhang P 

PROVIDER: S-EPMC11128713 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature